Neurelis
Neurelis, founded in 2007, specializes in central nervous system disorder treatments, offering a proprietary drug delivery technology and FDA-approved VALTOCO for seizure clusters.
Founding History of Neurelis
Neurelis was founded in 2007 with a mission to address the unmet needs of patients with central nervous system disorders. Over the years, Neurelis has developed a robust portfolio of proprietary technologies and products aimed at enhancing drug delivery and patient care.
Neurelis Technology Portfolio
Neurelis's technology portfolio includes Intravail®, ProTek®, and Hydrogel™. These proprietary technologies are designed to enhance drug delivery, making treatments more efficient and effective. Intravail® facilitates the non-invasive delivery of a wide range of drugs, while ProTek® and Hydrogel™ serve to improve the stability and bioavailability of therapeutic agents.
VALTOCO® (Diazepam Nasal Spray)
VALTOCO® is an FDA-approved diazepam nasal spray indicated for the treatment of seizure clusters. This product leverages Neurelis's Intravail® technology to enhance nasal delivery. VALTOCO® is available in four different treatment doses and offers a well-established history of diazepam use. It is licensed for use outside the US in multiple countries through partnerships with China Medical System and AculysPharma.
Neurelis Services and Support Programs
Neurelis offers several patient support programs including myNEURELIS, which provides individualized support for those prescribed VALTOCO®. Additionally, Neurelis has a partnership with Maxor Specialty Pharmacy to ensure VALTOCO® is delivered directly to patients' doorsteps. For eligible patients, Neurelis also offers copay assistance and a patient assistance program to help make treatments more accessible.